288259-76-7

Upstream product

• 6223-78-5 2,5-dichloro-2,5-dimethyl hexane 
• 2113-57-7 3-bromobiphenyl 
• 27452-17-1 6-bromo-1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene 
• 853998-14-8 4,4,5,5-tetramethyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,2-dioxaborolane 
• 108-36-1 1,3-dibromobenzene 

Downstream Products

• 288259-77-8 ethyl 4-[3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoate 
• 1312459-92-9 4-[3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE

The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of sphingosine kinase. Particularly, although not exclusively, the present invention also relates to pharmaceutical compositions comprising th

4-[3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoi c acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor α agonists

Aromatic retinoids having a meta-substituted aromatic ring bridge, such as 4-[3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and its 3,5-diaryl-substituted 4,5-dihydroisoxazole analogue, function as retinoid receptor panagonists by activating both retinoic acid and retinoid X receptors to induce gene transcription, and thereby provide novel scaffolds for retinoid drug development. Both classes of these ligand-inducible transcription factors are involved in mediating the inhibitory effects of retinoids on cancer cell growth. (C) 2000 Elsevier Science Ltd. All rights reserved.